{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:16:53Z","timestamp":1789463813787,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cathet Cardio Intervent"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Adverse cardiovascular outcomes remain common among patients undergoing mitral transcatheter edge\u2010to\u2010edge repair (M\u2010TEER). Despite growing evidence supporting the cardiovascular benefits of sodium\u2010glucose cotransporter\u20102 inhibitors (SGLT2i), large\u2010scale clinical data evaluating their efficacy in this specific population are limited. We aimed to assess cardiovascular outcomes associated with SGLT2i use compared with standard care using a large global research network database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using de\u2010identified patient data from the TriNetX Global Research Network. Adult patients (\u2265\u200918 years) undergoing M\u2010TEER were included and stratified into SGLT2i and usual care cohorts according to documented SGLT2i exposure before the index M\u2010TEER procedure. Propensity score matching (PSM) was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to evaluate efficacy and safety outcomes at 6 months and 1\u2010year follow\u2010up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 6793 patients undergoing M\u2010TEER were identified, of whom 2192 received SGLT2i therapy. After PSM, 1407 patients remained in each cohort. At 6 months, the primary composite outcome (stroke, all\u2010cause mortality, and acute heart failure) showed no significant difference between groups (HR 0.90,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.508). However, significant reductions were observed in all\u2010cause mortality (HR 0.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) and all\u2010cause hospitalizations (HR 0.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At 1 year, the primary composite outcome remained nonsignificant (HR 0.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.244), while reductions in all\u2010cause mortality (HR 0.76,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) and all\u2010cause hospitalizations (HR 0.83,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) persisted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients undergoing M\u2010TEER, baseline SGLT2i use was associated with lower all\u2010cause mortality and hospitalization in this observational cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ccd.70852","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:14:00Z","timestamp":1789460040000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Sodium Glucose Cotransporter\u20102 Inhibitors in Patients Undergoing Mitral Transcatheter Edge\u2010to\u2010Edge Repair"],"prefix":"10.1002","author":[{"given":"Farah","family":"Yasmin","sequence":"first","affiliation":[{"name":"Yale School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6237-0221","authenticated-orcid":false,"given":"Mohammad","family":"Hamza","sequence":"additional","affiliation":[{"name":"Guthrie Medical Group Sayre Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1468-4388","authenticated-orcid":false,"given":"Muhammad Ahmed Ali","family":"Fahim","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2304-2196","authenticated-orcid":false,"given":"Barka","family":"Sajid","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9924-4376","authenticated-orcid":false,"given":"Mahnoor","family":"Humayun","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Ochani","sequence":"additional","affiliation":[{"name":"SUNY Upstate University Hospital Syracuse New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2030","authenticated-orcid":false,"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[{"name":"AdventHealth Sebring Sebring Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-4566","authenticated-orcid":false,"given":"M. Chadi","family":"Alraies","sequence":"additional","affiliation":[{"name":"Detroit Medical Centre Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"8","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jacc.2009.03.077","article-title":"Percutaneous Mitral Repair With the MitraClip System","volume":"54","author":"Feldman T.","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"20","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jcin.2020.06.058","article-title":"NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure","volume":"13","author":"Giustino G.","year":"2020","journal-title":"JACC Cardiovascular Interventions"},{"issue":"2","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007552","article-title":"Outcomes After Transcatheter Mitral Valve Repair in Patients With Renal Disease","volume":"12","author":"Shah B.","year":"2019","journal-title":"Circulation. Cardiovascular Interventions"},{"issue":"8","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2021.03.011","article-title":"Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure","volume":"9","author":"Shahim B.","year":"2021","journal-title":"JACC. Heart Failure"},{"issue":"23","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium\u2010Glucose Cotransporter\u20102 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART\u2010C Collaborative Meta\u2010Analysis","volume":"149","author":"Patel S. M.","year":"2024","journal-title":"Circulation"},{"issue":"15","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients With Chronic Kidney Disease","volume":"383","author":"Heerspink H. J. L.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray J. J. V.","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacc.2011.08.067","article-title":"Acute and 12\u2010Month Results With Catheter\u2010Based Mitral Valve Leaflet Repair","volume":"59","author":"Whitlow P. L.","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2967\/jnmt.119.227819","article-title":"Review of HIPAA, Part 1: History, Protected Health Information, and Privacy and Security Rules","volume":"47","author":"Moore W.","year":"2019","journal-title":"Journal of Nuclear Medicine Technology"},{"issue":"1","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.31486\/toj.19.0095","article-title":"Exemptions and Limited Institutional Review Board Review: A Practical Look at the 2018 Common Rule Requirements for Exempt Research","volume":"20","author":"Walch\u2010Patterson A.","year":"2020","journal-title":"Ochsner Journal"},{"issue":"4","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"61","author":"Elm E.","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A Comparison of 12 Algorithms for Matching on the Propensity Score","volume":"33","author":"Austin P. C.","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"4","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E\u2010Value","volume":"167","author":"VanderWeele T. J.","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"36","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh T. A.","year":"2021","journal-title":"European Heart Journal"},{"issue":"18","key":"e_1_2_13_16_1","first-page":"895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich P. A.","year":"2022","journal-title":"Circulation"},{"issue":"15","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure","volume":"383","author":"Packer M.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.124.069144","article-title":"Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial","volume":"149","author":"Kang D. H.","year":"2024","journal-title":"Circulation"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"c3920","DOI":"10.1136\/bmj.c3920","article-title":"Definition, Reporting, and Interpretation of Composite Outcomes in Clinical Trials: Systematic Review","volume":"341","author":"Cordoba G.","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal Time Bias in Pharmaco\u2010Epidemiology","volume":"167","author":"Suissa S.","year":"2008","journal-title":"American Journal of Epidemiology"},{"issue":"2","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients With Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt D. L.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon S. D.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"e_1_2_13_23_1","first-page":"B9","article-title":"TCT\u2010185 Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge\u2010to\u2010Edge Repair","volume":"84","author":"Thakkar S.","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 Inhibitors on Stroke and Its Subtypes in Patients With Type 2 Diabetes: A Systematic Review and Meta\u2010Analysis","volume":"11","author":"Tsai W. H.","year":"2021","journal-title":"Scientific Reports"},{"issue":"10166","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta\u2010Analysis of Cardiovascular Outcome Trials","volume":"393","author":"Zelniker T. A.","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","article-title":"Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta\u2010Analysis of Randomized Controlled Trials","volume":"79","author":"Zheng R. J.","year":"2022","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"6","key":"e_1_2_13_27_1","first-page":"569","article-title":"The Prevalence and Impact of Atrial Fibrillation on 1\u2010Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair","volume":"12","author":"Arora S.","year":"2019","journal-title":"JACC: Cardiovascular Interventions"},{"issue":"3","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/dom.16122","article-title":"Effects of Sodium\u2010Glucose Cotransporter\u20102 Inhibitors in Myocardial Infarction Patients: A Systematic Review and Meta\u2010Analysis","volume":"27","author":"Jia Q.","year":"2025","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"7","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","volume":"23","author":"Salvatore T.","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7812\/TPP\/22.137","article-title":"Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real\u2010World Evidence Study","volume":"27","author":"Blanco C. A.","year":"2023","journal-title":"Permanente Journal"},{"issue":"5","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 Inhibitors on Cardiovascular, Renal and Safety Outcomes in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta\u2010Analysis","volume":"21","author":"Toyama T.","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"3","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","article-title":"SGLT2 Inhibitors and Renal Outcomes in Type 2 Diabetes With or Without Renal Impairment: A Systematic Review and Meta\u2010Analysis","volume":"12","author":"Seidu S.","year":"2018","journal-title":"Primary Care Diabetes"},{"key":"e_1_2_13_33_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.986186","article-title":"Cardiovascular and Renal Outcomes With Sodium Glucose Co\u2010Transporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A System Review and Network Meta\u2010Analysis","volume":"13","author":"Tian L.","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","volume":"134","author":"Heerspink H. J. L.","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"e_1_2_13_35_1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal B.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"e_1_2_13_36_1","first-page":"2530","article-title":"Combined Impact of Residual Mitral Regurgitation and Gradient After Mitral Valve Transcatheter Edge\u2010to\u2010Edge Repair","volume":"17","author":"Singh G. D.","year":"2024","journal-title":"JACC: Cardiovascular Interventions"},{"issue":"24","key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic V.","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman B.","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_13_39_1","doi-asserted-by":"crossref","DOI":"10.1177\/1479164120953625","article-title":"Risk of Orthostatic Hypotension Associated With Sodium\u2010Glucose Cotransporter\u20102 Inhibitor Treatment: A Meta\u2010Analysis of Randomized Controlled Trials","volume":"17","author":"Rong X.","year":"2020","journal-title":"Diabetes & Vascular Disease Research"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccd.70852","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:14:05Z","timestamp":1789460045000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.70852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":38,"alternative-id":["10.1002\/ccd.70852"],"URL":"https:\/\/doi.org\/10.1002\/ccd.70852","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"2025-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ccd.70852"}}